

February 6, 2026

IMMUNOLOGY

Cyclic Citrullinated Peptide Antibody (CCP)**Date effective: February 10, 2026****Clinical Practice Change:**

The Shared Health Immunology Laboratory at St Boniface Hospital will be changing its testing platform for CCP antibody testing.

Background Information:

Aids in the evaluation of rheumatoid arthritis. Use of the anti-CCP assay in association with RF assay maximizes the sensitivity/specificity ratio. It must not be forgotten that 15-20% of RAs are positive for RF but negative for anti-CCP and that about half of the RAs negative for RF are anti-CCP positive. Simultaneous positivity for RF and CCP has a positive predictive value of 100%. Serial monitoring of RA patients who are positive for anti-CCP is not appropriate as these autoantibodies do not correlate with clinical course or with response to drug treatment.

Changes in Test Procedure:

1. Testing for CCP will be changing from an ELISA to a Chemiluminescent (CLIA) method.

References/Resources:

Test: CCP [Laboratory Information Manual - CCP](#)
Delphic Code: CCP
Delphic Labels: CLIA
Sample: Serum 1.0 ml
Normal Range: 0.0 –4.9 AU/ml
Availability: Weekdays (3-5day TAT)
Requisition: [Immunology Autoimmune Laboratory Requisition](#)

Patient Impact:

- As no international reference serum exists for antibodies against CCP, the calibration and reporting is in arbitrary units (AU/ml). There is no linear correlation between the CLIA and ELISA methods.

System Improvements:

1. Improved TAT

Contact Information:

- Dr. Ping Sun, Hematopathologist, Medical Director Hematology & Immunology, Shared Health Manitoba, (phone: 204-787-4682) psun@sharedhealthmb.ca
- Jason Warren, Immunology Technical Director, Shared Health Manitoba, (phone: 204-471-0370) jwarren3@sharedhealthmb.ca